AP26113,
brigatinib,
AP26113,
1197958-12-5,
ALK-IN-1,
UNII-3DGD69C6PV,
3DGD69C6PV,
CHEMBL3397300,
(2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide,
5-chloro-2-N-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl]-4-N-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine,
5-Chloro-N~2~-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-N~4~-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine,
2,4-Pyrimidinediamine, 5-chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-,
2,4-Pyrimidinediamine, 5-chloro-N2-[4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl]-N4-[2-(dimethylphosphinyl)phenyl]-,
AP26113-analog,
Tube723,
compound 11q [PMID: 27144831],
Brigatinib(AP26113),
C26H34ClN6O2P,
GTPL7741,
SCHEMBL11916416,
DTXSID30725416,
EX-A770,
AP26113;ALK-IN-1,
HMS3652H14,
BCP06648,
AP26113-analog (ALK-IN-1),
2218AH,
ABP001163,
BDBM50062357,
MFCD23704187,
s7000,
ZINC89630357,
AKOS025401944,
AKOS032949980,
AP 26113-analog, Brigatinib-analog,
CS-1368,
SB16487,
KS-0000062T,
NCGC00351602-05,
NCGC00351602-09,
5-Chloro-N2-(4-(4-(dimethylamino)-1-piperidinyl)-2-methoxyphenyl)-N4-(2-(dimethylphosphinyl)phenyl)-2,4-pyrimidinediamine,
AC-27470,
BC600505,
HY-13464,
QC-11659,
FT-0696829,
SW219566-1,
A11948,
W-6025,
5-chloro-2-N-{4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}-4-N-[2-(dimethylphosphoryl)phenyl]pyrimidine-2,4-diamine,
5-Chloro-N2-(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-N4-(2-(dimethylphosphoryl)phenyl)pyrimidine-2,4-diamine,
E5J,
Brigatinib,
ALUNBRIG,
D0O9PQ,
AP-26113,
ACN-031540,
A1367,